Table 3 Clinical response of individual patients after monotherapy, monotherapy plus Avastin or combination therapy
Non-Responder | Responder | ||||||
|---|---|---|---|---|---|---|---|
Patient | Substance | CTR-Test | Patient | Substance | CTR-Test | ||
Monotherapy | |||||||
1 | Carbo | ER | 13 | Pac | SR | ||
2 | Caelyx | SR | 14 | Carbo | SR | ||
3 | Topo | SR | 15 | Topo | SR | ||
4 | Carbo | SR | 16 | Pac | MR | ||
5 | Topo | MR | |||||
6 | Topo | MR | |||||
7 | Caelyx | MR | |||||
8 | Caelyx | ER | |||||
9 | Caelyx | MR | |||||
10 | Topo | SR | |||||
11 | Topo | ER | |||||
12 | Topo | ER | |||||
(Mono) | |||||||
1 | Caelyx + Avastin | SR | 2 | Caelyx + Avastin | SR | ||
3 | Topo + Avastin | MR | |||||
Combination Chemotherapy | |||||||
Patient | Substance | CTR-Test | Scorea | Patient | Substance | CTR-Test | Scorea |
1 | Carbo/Pac | ER/ER | 0 | 9 | Carbo/Caelyx | SR/SR | 4 |
2 | Carbo/Caelyx | MR/ER | 1 | 10 | Carbo/Gem | SR/SR | 4 |
3 | Carbo/Gem | ER/ER | 0 | 11 | Carbo/Pac | SR/SR | 4 |
4 | Carbo/Pac | SR/SR | 4 | 12 | Carbo/Caelyx | SR/ER | 2 |
5 | Carbo/Gem | ER/ER | 0 | 13 | Carbo/Caelyx | SR/ER | 2 |
6 | Carbo/Pac | ER/SR | 2 | 14 | Carbo/Caelyx | SR/MR | 3 |
7 | Carbo/Caelyx | MR/ER | 1 | 15 | Carbo/Caelyx | SR/SR | 4 |
8 | Carbo/Pac | MR/ER | 1 | 16 | Carbo/Pac | MR/ER | 1 |
17 | Carbo/Pac | SR/MR | 3 | ||||
18 | Carbo/Caelyx | MR/SR | 3 | ||||
19 | Carbo/Caelyx | SR/SR | 4 | ||||
20 | Carbo/Pac | SR/MR | 3 | ||||
21 | Carbo/Caelyx | SR/MR | 3 | ||||
22 | Carbo/Gem | ER/SR | 2 | ||||
23 | Carbo/Pac | SR/SR | 4 | ||||
24 | Carbo/Caelyx | MR/MR | 2 | ||||
25 | Carbo/Pac | SR/MR | 3 | ||||
26 | Carbo/Caelyx | MR/MR | 2 | ||||
27 | Carbo/Caelyx | SR/MR | 3 | ||||
28 | Carbo/Pac | SR/MR | 3 | ||||
29 | Carbo/Pac | SR/MR | 3 | ||||
30 | Carbo/Pac | SR/SR | 4 | ||||
31 | Carbo/Pac | SR/SR | 4 | ||||
32 | Carbo/Pac | ER/SR | 2 | ||||
33 | Carbo/Caelyx | SR/SR | 4 | ||||